|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 19507 |
FusionGeneSummary for LATS2_MYLK |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: LATS2_MYLK | Fusion gene ID: 19507 | Hgene | Tgene | Gene symbol | LATS2 | MYLK | Gene ID | 26524 | 4638 |
| Gene name | large tumor suppressor kinase 2 | myosin light chain kinase | |
| Synonyms | KPM | AAT7|KRP|MLCK|MLCK1|MLCK108|MLCK210|MSTP083|MYLK1|smMLCK | |
| Cytomap | 13q12.11 | 3q21.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein kinase LATS2LATS (large tumor suppressor, Drosophila) homolog 2LATS, large tumor suppressor, homolog 2kinase phosphorylated during mitosis proteinlarge tumor suppressor homolog 2serine/threonine kinase KPMserine/threonine-pr | myosin light chain kinase, smooth musclekinase-related proteinmyosin, light polypeptide kinasesmooth muscle myosin light chain kinasetelokin | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q9NRM7 | Q15746 | |
| Ensembl transtripts involved in fusion gene | ENST00000382592, ENST00000542899, ENST00000472754, | ENST00000360772, ENST00000359169, ENST00000360304, ENST00000418370, ENST00000578202, ENST00000354792, ENST00000346322, ENST00000583087, ENST00000475616, ENST00000510775, | |
| Fusion gene scores | * DoF score | 2 X 2 X 2=8 | 9 X 10 X 3=270 |
| # samples | 3 | 12 | |
| ** MAII score | log2(3/8*10)=1.90689059560852 | log2(12/270*10)=-1.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: LATS2 [Title/Abstract] AND MYLK [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | LATS2 | GO:0000082 | G1/S transition of mitotic cell cycle | 12853976 |
| Hgene | LATS2 | GO:0006468 | protein phosphorylation | 10871863 |
| Hgene | LATS2 | GO:0009755 | hormone-mediated signaling pathway | 15131260 |
| Hgene | LATS2 | GO:0035329 | hippo signaling | 20412773 |
| Hgene | LATS2 | GO:0035556 | intracellular signal transduction | 10871863 |
| Hgene | LATS2 | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 12853976 |
| Tgene | MYLK | GO:0030335 | positive regulation of cell migration | 19826488 |
| Tgene | MYLK | GO:0051928 | positive regulation of calcium ion transport | 16284075 |
| Tgene | MYLK | GO:0071476 | cellular hypotonic response | 11976941 |
| Tgene | MYLK | GO:0090303 | positive regulation of wound healing | 15825080 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | SARC | TCGA-K1-A42X-02A | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| TCGA | RV | SARC | TCGA-K1-A42X-01A | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5UTR-3CDS | ENST00000382592 | ENST00000360772 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-3CDS | ENST00000382592 | ENST00000359169 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-3CDS | ENST00000382592 | ENST00000360304 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-intron | ENST00000382592 | ENST00000418370 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-intron | ENST00000382592 | ENST00000578202 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-intron | ENST00000382592 | ENST00000354792 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-intron | ENST00000382592 | ENST00000346322 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-intron | ENST00000382592 | ENST00000583087 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-intron | ENST00000382592 | ENST00000475616 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| 5UTR-5UTR | ENST00000382592 | ENST00000510775 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-3CDS | ENST00000542899 | ENST00000360772 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-3CDS | ENST00000542899 | ENST00000359169 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-3CDS | ENST00000542899 | ENST00000360304 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000542899 | ENST00000418370 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000542899 | ENST00000578202 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000542899 | ENST00000354792 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000542899 | ENST00000346322 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000542899 | ENST00000583087 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000542899 | ENST00000475616 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-5UTR | ENST00000542899 | ENST00000510775 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-3CDS | ENST00000472754 | ENST00000360772 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-3CDS | ENST00000472754 | ENST00000359169 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-3CDS | ENST00000472754 | ENST00000360304 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000472754 | ENST00000418370 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000472754 | ENST00000578202 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000472754 | ENST00000354792 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000472754 | ENST00000346322 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000472754 | ENST00000583087 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-intron | ENST00000472754 | ENST00000475616 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
| intron-5UTR | ENST00000472754 | ENST00000510775 | LATS2 | chr13 | 21635485 | - | MYLK | chr3 | 123386034 | - |
Top |
FusionProtFeatures for LATS2_MYLK |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| LATS2 | MYLK |
| Negative regulator of YAP1 in the Hippo signalingpathway that plays a pivotal role in organ size control and tumorsuppression by restricting proliferation and promoting apoptosis.The core of this pathway is composed of a kinase cascade whereinSTK3/MST2 and STK4/MST1, in complex with its regulatory proteinSAV1, phosphorylates and activates LATS1/2 in complex with itsregulatory protein MOB1, which in turn phosphorylates andinactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation ofYAP1 by LATS2 inhibits its translocation into the nucleus toregulate cellular genes important for cell proliferation, celldeath, and cell migration. Acts as a tumor suppressor which playsa critical role in centrosome duplication, maintenance of mitoticfidelity and genomic stability. Negatively regulates G1/Stransition by down-regulating cyclin E/CDK2 kinase activity.Negative regulator of the androgen receptor. Phosphorylates SNAI1in the nucleus leading to its nuclear retention and stabilization,which enhances its epithelial-mesenchymal transition and tumorcell invasion/migration activities. This tumor-promoting activityis independent of its effects upon YAP1 or WWTR1/TAZ.{ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:12853976,ECO:0000269|PubMed:15131260, ECO:0000269|PubMed:18158288,ECO:0000269|PubMed:21952048}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for LATS2_MYLK |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for LATS2_MYLK |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| LATS2 | WWC1, LATS1, ELAVL1, YAP1, AR, AURKB, AURKA, PPP1R13B, MOB1A, MOB1B, MOB3A, MOB3B, MOB3C, MOB4, CHEK1, CHEK2, YWHAG, STK3, MDM2, SNAI1, AMOTL2, HIST2H2BE, HRAS, AJUBA, DYRK1A, CDK2, ALDH18A1, ALMS1, AMOT, AMOTL1, ANAPC1, ANAPC5, APC, CEP131, BAG2, BAG5, CCDC77, CCDC85C, CCDC88C, CCP110, CENPJ, CEP192, CEP72, CEP85, CEP89, CGN, CNTROB, CPVL, CSPP1, CTNNB1, CUL7, CYLD, DCAF7, DNAJA3, EIF4ENIF1, ERC1, AMER1, FBXL16, FUBP3, GIGYF1, GRIP1, IFFO1, INADL, KIAA0368, KIAA1462, KIAA1549, KIAA1671, CEP295, LATS2, LETM1, LIMD1, LIN7C, LNX2, LONP1, LZTS2, MAGI1, MIA3, MIPOL1, MLLT4, MPDZ, MPHOSPH9, MPP5, NCKAP5L, NIN, NINL, NME7, NOTCH1, NOTCH2, NUP160, OFD1, PAK4, PARD3, PCM1, PDZD11, PHLDB2, PKP4, PLEKHA1, PLEKHA5, PLEKHA7, PLEKHG1, PLOD1, PNMA2, PPFIA1, PPFIBP1, PPP2R1A, PPP2R2A, PTPN13, PTPN14, RADIL, RASAL2, RBM15, RCN2, SDCCAG3, SEC16A, SIPA1L1, SIPA1L2, SIPA1L3, SKP1, SKP2, SORBS1, SPICE1, SSX2IP, STK4, STXBP4, TANC2, TBK1, TBKBP1, TCHP, TJP1, TJP2, TNRC6B, TP53BP2, TRIM27, TRIM37, TUBB2A, TUBB6, USP54, USP9X, UTRN, YWHAH, SAV1, HSP90AB1, TAZ, ABL1, CDKN1A, NF2, WTIP, WWC2, WWC3, CEP128, RASSF1, SIAH1, SKI, WWTR1, KIF23, NEDD4, IKBKB, ZYX, SIAH2, EZH2, SUZ12 | MYLK | PRKG2, CALM1, CTTN, PAK1, MLC1, SRC, ALK, MYC, TP53, GOPC, HSPB1, MYH9, PPP1CB, ANLN, MYO19 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for LATS2_MYLK |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for LATS2_MYLK |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | LATS2 | C0004114 | Astrocytoma | 1 | CTD_human |
| Tgene | MYLK | C0027626 | Neoplasm Invasiveness | 2 | CTD_human |
| Tgene | MYLK | C0027627 | Neoplasm Metastasis | 2 | CTD_human |
| Tgene | MYLK | C0017178 | Gastrointestinal Diseases | 1 | CTD_human |
| Tgene | MYLK | C0017601 | Glaucoma | 1 | CTD_human |
| Tgene | MYLK | C0017638 | Glioma | 1 | CTD_human |
| Tgene | MYLK | C0020443 | Hypercholesterolemia | 1 | CTD_human |
| Tgene | MYLK | C0020517 | Hypersensitivity | 1 | CTD_human |
| Tgene | MYLK | C0032285 | Pneumonia | 1 | CTD_human |
| Tgene | MYLK | C0042373 | Vascular Diseases | 1 | CTD_human |
| Tgene | MYLK | C0242488 | Acute Lung Injury | 1 | CTD_human |
| Tgene | MYLK | C1527311 | Brain Edema | 1 | CTD_human |
| Tgene | MYLK | C3151077 | AORTIC ANEURYSM, FAMILIAL THORACIC 7 | 1 | UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|